SEC Form DFiling only, no announcement found
Kura Oncology, based in San Diego, CA, reported $5,000,000 sold in a private offering of equity, with the first sale on November 9, 2026, in a Form D filed with the SEC on November 18, 2026. The filing says 1 investor has already invested. The offering authorizes up to $25,000,000.
Legal name on the filing: Kura Oncology, Inc.. Formerly ZETA ACQUISITION CORP III.
| Amount sold | $5,000,000Basis: Form D total amount sold, as of the filing of November 18, 2026. Not the announced round size. |
|---|---|
| Total offering | $25,000,000The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $20,000,000 |
| Securities offered | Equity |
| Exemption claimed | Rule 506(b) |
| Date of first sale | November 9, 2026 |
| Investors already invested | 1 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Biotechnology |
| Principal place of business | San Diego, CA |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | over five years ago |
| Revenue range | Decline to Disclose |
| SEC CIK | 1422143 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Troy Wilson | Executive Officer, Director | None linked |
| Kathleen Ford | Executive Officer | None linked |
| Jennifer Fulk | Executive Officer | None linked |
| Francis Burrows | Executive Officer | None linked |
| Mollie Leoni | Executive Officer | None linked |
| Teresa Bair | Executive Officer | None linked |
| Brian Powl | Executive Officer | None linked |
| Faheem Hasnain | Director | None linked |
| Helen Collins | Director | None linked |
| Thomas Malley | Director | None linked |
| Diane Parks | Director | None linked |
| Carol Schafer | Director | None linked |
| Mary Szela | Director | None linked |
| Michael Vasconcelles | Director | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Nov 18, 2026 | D (original) | $5,000,000 | $25,000,000 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through November 18, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "Kura Oncology: SEC Form D deal record", https://vcbeast.com/deals/kura-oncology-form-d-2026-11-09. Source: SEC EDGAR, accession 0001231919-26-001602.